L3VLUP
ProSign in

IONS · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IONSLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IONS
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterIONSLLY
Q3 202015 holders, $2.1bn33 holders, $14.1bn
Q4 202014 holders, $2.5bn29 holders, $17.3bn
Q1 20219 holders, $1.9bn24 holders, $23.0bn
Q2 202110 holders, $1.8bn24 holders, $27.8bn
Q3 20218 holders, $1.4bn31 holders, $29.9bn
Q4 20219 holders, $1.3bn31 holders, $34.7bn
Q1 20229 holders, $1.6bn24 holders, $35.3bn
Q2 202212 holders, $1.6bn33 holders, $42.7bn
Q3 202211 holders, $1.5bn31 holders, $43.4bn
Q4 20229 holders, $1.2bn31 holders, $46.6bn
Q1 20237 holders, $1.0bn33 holders, $44.3bn
Q2 202310 holders, $1.3bn37 holders, $59.6bn
Q3 202312 holders, $1.4bn44 holders, $67.6bn
Q4 202314 holders, $1.9bn45 holders, $73.6bn
Q1 202415 holders, $1.7bn41 holders, $95.3bn
Q2 202417 holders, $2.1bn43 holders, $110bn
Q3 202416 holders, $2.1bn45 holders, $107bn
Q4 202411 holders, $1.7bn46 holders, $93.9bn
Q1 202510 holders, $1.5bn42 holders, $98.4bn
Q2 202513 holders, $2.1bn43 holders, $93.2bn
Q3 202518 holders, $3.6bn39 holders, $86.7bn
Q4 202515 holders, $4.9bn41 holders, $123bn
Q1 202616 holders, $5.0bn39 holders, $106bn
Q2 202613 holders, $5.5bn44 holders, $132bn
IONS

Ionis Pharmaceuticals Inc

Holders
16
Reported value
$2.1bn
Buyers
11
Sellers
7

Breadth +4 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
45
Reported value
$107bn
Buyers
24
Sellers
22

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 48 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only IONS (3)

ARK Investment Management LLC, Baillie Gifford & Co, PDT Partners LLC

Only LLY (32)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, GAMCO Investors Inc, Holocene Advisors LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Polen Capital Management LLC, Quantbot Technologies LP, Renaissance Technologies LLC, Rokos Capital Management LLP, and 7 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →